Alterity Therapeutics Welcomes New Chief Financial Officer
Alterity Therapeutics, a biotechnology company focused on innovative solutions for neurodegenerative diseases, has shared exciting news regarding its leadership team. Today marks the official appointment of Abby Macnish Niven as the new Chief Financial Officer (CFO). In her role, she will be pivotal in driving the company’s financial strategies to further its mission of improving patient outcomes.
Leadership Insights
David Stamler, M.D., the CEO of Alterity, expressed enthusiasm about Abby's arrival, stating, “Abby’s broad experience and financial expertise will be invaluable as we work to advance our programs. I also extend my gratitude to Phillip Hains and his team for their support during this transition.” With a strong financial background, Niven’s leadership is expected to guide Alterity Therapeutics in navigating the complexities of the biotechnology sector.
Abby Macnish Niven’s Professional Background
Ms. Macnish Niven comes with a wealth of experience in private wealth management, honed through her work with leading financial institutions such as ANZ, UBS, and Ord Minett. Her consulting work spans various listed and unlisted companies, covering governance, finance, and corporate structures. With degrees in Commerce and Science from the University of Western Australia and her status as a Chartered Financial Analyst, she brings a robust skill set to her new role at Alterity.
Transition and Future Directions
Abby replaces Phillip Hains, who served as CFO since December 2023 and will continue contributing as the Company Secretary. This strategic change is aimed at strengthening Alterity’s financial management capabilities as the company develops treatments for diseases like Parkinson’s. Currently, their lead compound, ATH434, is being explored in two Phase 2 clinical trials targeting Multiple System Atrophy, an aggressive form of neurodegenerative disease.
About Alterity Therapeutics
Alterity Therapeutics is at the forefront of biotechnology research, passionately dedicated to crafting disease-modifying treatments for neurodegenerative diseases. Their lead asset, ATH434, offers promise in tackling various Parkinsonian disorders, demonstrating the company’s commitment to improving the lives of those affected by these challenging conditions. Alongside this, Alterity fosters a comprehensive drug discovery platform, generating innovative compounds aimed at addressing the fundamental pathologies associated with neurological diseases.
Community and Global Engagement
With a strong foundation in Australia and the United States, Alterity is poised for significant impact in the global healthcare landscape. Their dedication not only lies in research but also in fostering relationships with the communities they serve to enhance awareness and education surrounding neurodegenerative diseases.
Contact Information
For inquiries related to investor relations or media, interested parties can reach out via:
Australia Contact: Hannah Howlett
Phone: +61 450 648 064
Email: we-aualteritytherapeutics@we-worldwide.com
U.S. Contact: Remy Bernarda
Phone: +1 (415) 203-6386
Email: remy.bernarda@iradvisory.com
Frequently Asked Questions
Who is Abby Macnish Niven?
Abby Macnish Niven is the newly appointed Chief Financial Officer of Alterity Therapeutics, bringing extensive financial expertise to the role.
What role will Abby Macnish Niven play at Alterity?
She will oversee the financial strategies and management of the company, helping advance its therapeutic programs.
What is ATH434?
ATH434 is Alterity's lead clinical compound being developed to treat various Parkinsonian disorders.
Where is Alterity Therapeutics located?
The company has bases in both Melbourne, Australia, and San Francisco, California, USA.
What are the future plans for Alterity Therapeutics?
Alterity aims to advance its drug development programs, with a strong focus on clinical trials and innovative treatments for neurodegenerative diseases.
